Zhang Y, Wang Y, Peng J, Zhao K, Li L, Zhang Y
Front Oncol. 2025; 15:1516867.
PMID: 39990687
PMC: 11842334.
DOI: 10.3389/fonc.2025.1516867.
Zhang H, Guo H, Han F, Zheng Y
Am J Transl Res. 2025; 17(1):47-59.
PMID: 39959203
PMC: 11826170.
DOI: 10.62347/AOSK8903.
Bai Y, Li K, Peng J, Yi C
Life Med. 2025; 2(1):lnad008.
PMID: 39872957
PMC: 11749794.
DOI: 10.1093/lifemedi/lnad008.
King E, Panfil A
Viruses. 2025; 17(1).
PMID: 39861913
PMC: 11769288.
DOI: 10.3390/v17010124.
Kielbowski K, Bakinowska E, Goracy-Rosik A, Figiel K, Judek R, Rosik J
Epigenomes. 2025; 9(1.
PMID: 39846569
PMC: 11755448.
DOI: 10.3390/epigenomes9010002.
The interplay between RNA m6A modification and radiation biology of cancerous and non-cancerous tissues: a narrative review.
Cheng Y, Shang Y, Zhang S, Fan S
Cancer Biol Med. 2025; 21(12.
PMID: 39831771
PMC: 11745087.
DOI: 10.20892/j.issn.2095-3941.2024.0415.
Advanced reactivity-based sequencing methods for mRNA epitranscriptome profiling.
Cai Z, Song P, Yu K, Jia G
RSC Chem Biol. 2025; 6(2):150-169.
PMID: 39759443
PMC: 11694185.
DOI: 10.1039/d4cb00215f.
Distinct pathways utilized by METTL3 to regulate antiviral innate immune response.
Hao H, Zhang F, Chen Z, Tan Z, Zhang H, Feng X
iScience. 2025; 27(11):111071.
PMID: 39759074
PMC: 11700651.
DOI: 10.1016/j.isci.2024.111071.
m6A RNA modification pathway: orchestrating fibrotic mechanisms across multiple organs.
Huang X, Yu Z, Tian J, Chen T, Wei A, Mei C
Brief Funct Genomics. 2025; 24.
PMID: 39756462
PMC: 11735750.
DOI: 10.1093/bfgp/elae051.
Role of N6-methyladenosine methylation in nasopharyngeal carcinoma: current insights and future prospective.
Zhao Y, Li J, Dian M, Bie Y, Peng Z, Zhou Y
Cell Death Discov. 2024; 10(1):490.
PMID: 39695216
PMC: 11655975.
DOI: 10.1038/s41420-024-02266-y.
Epitranscriptomic RNA mA Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities.
Uddin M, Wang Z, Yang C
Adv Sci (Weinh). 2024; :e2403936.
PMID: 39661414
PMC: 11775542.
DOI: 10.1002/advs.202403936.
Regulation and application of mA modification in tumor immunity.
Xiong Q, Zhang Y, Zheng Y, Zhu Q
Sci China Life Sci. 2024; .
PMID: 39648245
DOI: 10.1007/s11427-024-2648-0.
Targeting METTL3 as a checkpoint to enhance T cells for tumour immunotherapy.
Wu K, Li S, Hong G, Dong H, Tang T, Liu H
Clin Transl Med. 2024; 14(11):e70089.
PMID: 39568154
PMC: 11578931.
DOI: 10.1002/ctm2.70089.
Recent advances in methylation modifications of microRNA.
Su N, Yu X, Duan M, Shi N
Genes Dis. 2024; 12(1):101201.
PMID: 39524539
PMC: 11550756.
DOI: 10.1016/j.gendis.2023.101201.
Dynamic multilayered control of mA RNA demethylase activity.
Jaafar C, Aguiar R
Proc Natl Acad Sci U S A. 2024; 121(46):e2317847121.
PMID: 39495907
PMC: 11572932.
DOI: 10.1073/pnas.2317847121.
Interplay of RNA mA Modification-Related Geneset in Pan-Cancer.
Zhang B, Hao Y, Liu H, Wu J, Lu L, Wang X
Biomedicines. 2024; 12(10).
PMID: 39457524
PMC: 11504890.
DOI: 10.3390/biomedicines12102211.
gene polymorphisms increase Wilms tumor risk in Chinese girls.
Deng C, Han Y, Zhou H, Zhang J, Cheng J, Li S
J Cancer. 2024; 15(18):6103-6109.
PMID: 39440064
PMC: 11493011.
DOI: 10.7150/jca.99928.
The three YTHDF paralogs and VIRMA are strong cross-histotype tumor driver candidates among mA core genes.
Destefanis E, Sighel D, Dalfovo D, Gilmozzi R, Broso F, Cappannini A
NAR Cancer. 2024; 6(4):zcae040.
PMID: 39411658
PMC: 11474903.
DOI: 10.1093/narcan/zcae040.
YTHDF3 modulates the progression of breast cancer cells by regulating FGF2 through mA methylation.
Gong R, Zhang Z, Sun T, Zhao Y, Fang W
Front Cell Dev Biol. 2024; 12:1438515.
PMID: 39372951
PMC: 11449838.
DOI: 10.3389/fcell.2024.1438515.
Reading mA marks in mRNA: A potent mechanism of gene regulation in plants.
Nguyen T, Kang H
J Integr Plant Biol. 2024; 66(12):2586-2599.
PMID: 39364713
PMC: 11622538.
DOI: 10.1111/jipb.13781.